March 14, 2011
In early-stage study results reported recently to investors, Gilead Sciences Inc. said its four-drug combination eliminated hepatitis C virus in patients. The trial examined the use of Gilead GS-9256 and GS-9190 with the standard drugs ribavirin and peginterferon. The researchers plan to present their findings at the annual meeting of the European Association for the Study of the Liver, which begins March 30 in Berlin.
San Francisco Chronicle
03.09.2011; Kristen Hallam, Bloomberg News
No comments have been made.
|Really Rapid Review -- AIDS 2016, Durban|
|Update on Genetic Engineering for an HIV Cure|
|Charlize Theron's 8 Quotable Moments About HIV at AIDS 2016|
|This Week in HIV Research: New Protein Could Shock and Kill Latent HIV, and Engineered T Cells Could Help Fight HIV|
|At AIDS 2016, the Global Village Rocks -- and Activists Party Without Pants|